Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.47 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28547335 | 0.84 | GPR119 (0.37) | GPR119PRMT5KDM4EMAPTWNT3A | |
| SCHEMBL23579942 | 0.83 | GPR119 (0.50) | GPR119PRMT5TRPV3THRBKDM4E | |
| SCHEMBL15939961 | 0.83 | GPR119 (0.50) | GPR119PRMT5TRPV3THRBKDM4E | |
| SCHEMBL23235678 | 0.83 | KMT2A (0.38) | MAPTGAASMN1; SMN2JAK2JAK3 | |
| SCHEMBL31627464 | 0.82 | GPR119 (0.52) | GPR119 | |
| SCHEMBL30378597 | 0.82 | GPR119 (0.48) | GPR119PRMT5TRPV3THRBKDM4E | |
| SCHEMBL3486530 | 0.81 | GPR119 (0.69) | GPR119MAPTGAASMN1; SMN2 | |
| SCHEMBL23928962 | 0.81 | GPR119 (0.51) | GPR119 | |
| SCHEMBL31705767 | 0.81 | TRPV3 (0.48) | GPR119PRMT5TRPV3THRBKDM4E | |
| SCHEMBL31627293 | 0.81 | GPR119 (0.69) | GPR119TRPV3THRBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025128834-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240132483-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| CN-116547279-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-113831337-B | GLP-1 receptor agonist, and pharmaceutical composition and use thereof | 广州市恒诺康医药科技有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-3806855-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-113831337-A | GLP-1 receptor agonist, and pharmaceutical composition and use thereof | 广州市恒诺康医药科技有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GPR119 4/4885PRMT5 900/4885TRPV3 1287/4885 |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GPR119 4/4885PRMT5 900/4885TRPV3 1287/4885 |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GPR119 11/4885PRMT5 4322/4885TRPV3 410/4885 |
| US-20240132483-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GPR119 4/4885PRMT5 900/4885TRPV3 1287/4885 |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GPR119 4/4885PRMT5 900/4885TRPV3 1287/4885 |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GPR119 4/4885PRMT5 900/4885TRPV3 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.